Literature DB >> 573405

Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.

R P Lesser, S Fahn, S R Snider, L J Cote, W P Isgreen, R E Barrett.   

Abstract

We evaluated the current status of 131 patients with idiopathic parkinsonism who were receiving levodopa therapy. The residual parkinsonian symptoms and signs were tabulated, as were the adverse effects from medication. Response to therapy was correlated with duration of the disease and with duration of treatment. Patients with on-off or wearing-off effects were likely to have been treated for 4 years or longer. Patients treated with levodopa for 4 to 8 years were significantly more impaired with parkinsonism than patients treated for 0 to 3 years, even when patients were matched for total duration of disease. These data suggest that the deterioration of responsiveness after several years of levodopa therapy may be due to the therapy itself. Our findings support the concept that utilization of levodopa therapy should be delayed until a patient becomes significantly impaired in occupational or social situations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 573405     DOI: 10.1212/wnl.29.9_part_1.1253

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  48 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

Authors:  Bonnie G Garcia; M Diana Neely; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2010-01-29       Impact factor: 5.357

3.  Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors:  M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

Authors:  M C Coldwell; I Boyfield; T Brown; J J Hagan; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 5.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

6.  Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms.

Authors:  M A Mena; M J Casarejos; A Carazo; C L Paíno; J García de Yébenes
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 7.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

8.  Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

Authors:  E Scholz; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

9.  Extrapyramidal side effects of clozapine and haloperidol.

Authors:  M Kurz; M Hummer; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 10.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.